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ABSTRACT
Objective: The objective of the study is acetylcholinesterase (AChE) inhibitory effect of 3-(1H-indol-3-yl)-1, 3-diphenylpropan-1-one derivatives by 
Ellman’s method, physostigmine is used as positive control.
Method: 3-(1H-indol-3-yl)-1, 3-diphenylpropan-1-one derivatives were synthesized by the addition of chalcone (0.25 g, 1 mmol), indole (0.12 g, 
1 mmol) in ethanol (5 ml), and concentrated hydrochloric acid (5 mmol %). These earlier synthesized compounds were screened for AChE inhibitors 
by modifying Ellman’s method.
Results: Among the tested compounds, 3a and 3j were found to be having more potential than other compounds with half maximal inhibitory 
concentration values of 13.64 and 14.3 µg/ml, respectively. Whereas, compounds 3c, 3e, 3g, and 3i exhibited an average AChE inhibition of 16.4, 17.9, 
17.6, and 21.1 µg/ml, respectively.
Conclusion: The compounds 3-(1H-indol-3-yl)-1, 3-diphenylpropan-1-one derivatives were found to be possible lead molecules in AChE inhibition 
and even though, the molecules were structurally dissimilar to that of the standard, still they exhibited a considerable degree of inhibition and 
encourage the researchers to look into the mode of action of their inhibition ability against AChE.
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INTRODUCTION
Alzheimer’s disease (AD), is the most common form of dementia, 
affecting millions of elderly people accounting for about 50-60% of 
the overall cases of dementia among persons over 65 years of age. 
AD is characterized by atrophy of the cerebral cortex and loss of 
hippocampal and neocortical neurons. It is characterized by memory 
deficit and progressive impairment of cognitive nerve functions [1] 
leading to mental deterioration, decrease in cognitive ability and severe 
behavioral, and psychological abnormalities such as irritability, anxiety, 
and depression [2]. Many factors have been found to be implicated in 
AD, such as low levels of acetylcholine (ACh) availability [3], β-amyloid 
deposits, decrease in oxidative phosphorylation process, and metal ion 
exchange process, which seem to play significant roles in the disease [4].
The therapies under evaluation for the treatment of AD have disease 
modifying and neuroprotective approaches [5]. The behavioral 
abnormalities are best treated first by non-pharmacological interventions. 
Pharmacological agents used for treatment of neuropsychiatric illnesses 
include antipsychotics, antidepressants, and mood stabilizers [6]. Current 
treatment of AD focus on increasing cholinergic neurotransmission in the 
brain by inhibiting cholinesterases (ChEs).
In this regard, acetylcholinesterase inhibitors (AChEI) are approved for 
the treatment of mild to moderate AD [7,8]. Four AChEI are approved by 
food and drug administration, they are tacrine, donepezil, rivastigmine, 
and gallantamine [9,10]. Unfortunately, the potential effectiveness is 
often limited by the side effects [11]. The care should be taken during AD 
treatment because it is related to the vital organ brain, its disorder with 
central nervous system (CNS). The challenge for this disorder is rational 
drug design in the discovery of mechanism-based inhibitors due to its role 
in the hydrolysis of the neurotransmitter ACh leading to senile dementia, 
related with selective loss of cholinergic nerve signals in the form of neurons, 
and reduced frequency of ACh neurotransmitter, especially in the CNS.
Due to the multi-pathogenesis of AD, one of the current strategies is 
to develop novel anti-AD agents with multiple potencies and target 
specificity [12]. Genistein is biosynthetic compound one of the simplest 
flavonoid form of the leguminosae [13]. It expresses a broad spectrum 
of pharmacological activities, such as antioxidant, anticancer, and 
antimicrobial [14-16]. In recent years, it was reported that genistein 
showed the neuroprotective effect and ameliorated learning and 
memory deficits in the AD rat model [17,18].
Hence, in an attempt to develop new molecules for the treatment of 
AD, new indole diphenylpropan-1-one derivatives 3a-j, was screened 
against AChE enzyme. The indole derivatives are known to possess 
different biological activities [19,20]. The derivatives 3a-j was reported 
earlier from our laboratory [21] and their pharmacological behavior; 
it was found that the derivatives were not promising enough to be 
considered for further investigation on the cell lines tested. This might 
be because of lacking in specificity or the competitiveness of molecules 
at the binding site of enzymes involved, because of racemic behavior. 
The synthesized derivatives were accompanying indole nucleus as a 
bioisosteric substitute of the diphenylpropan-1-one moiety which is 
reported to be important for AChEI activity [22].
Rationality
The literature survey revealed that the title compounds do possess 
considerable degree of biological activity [19,20]; hence, tested for 
antiproliferative activity [21]. The title compounds were found to be 
moderately active against the cell lines tested. This prompted us to 
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further take up the molecules in the in vitro AChEI activity by random 
screening against the enzyme. The in silico adsorption, distribution, 
metabolism, excretion, and toxicity studies also strengthen our claim 
that the molecules are potentially safe through oral absorption. Hence, 
the present investigation was envisaged to screen the 3-(1H-indol-3-
yl)-1, 3-diphenylpropan-1-ones derivatives for their AchE inhibitory 
activity.
METHODS
The synthesis of 3-(1H-indol-3-yl)-1, 3-diphenylpropan-1-one 3a-j 
were reported earlier from our laboratory [21].
Schematic representation of the already synthesized 3-(1H-indol-3-yl)-1, 
3-diphenylpropan-1-ones derivatives 3a-j [21].
CHEMICALS
Acetylthiocholine iodide (ATCI), 5,5’–dithio-bis-2-nitrobenzoic acid 
(DTNB), bovine serum albumin (BSA), and electric eel AChE (AChE; 
EC 3.1.17; lyophilized, 500 U/vial solid, 65 U/mg) were purchased 
from Sigma. Physostigmine was used as the positive control. Buffers 
and other chemical were of extra pure analytical grade. The following 
buffers were used: Buffer A: 50 mmol Tris–HCl, pH 8, containing 0.1% 
BSA; Buffer B: 50 mmol Tris- HCl, pH 8 containing 0.1 M NaCl, 0.02 M 
MgCl2 × 6H2O.
ENZYME INHIBITION ASSAY
The synthesized compounds 3a-j (Table 1) were screened against AChE 
in vitro screening according to the modified Ellman’s method [23,24]. 
Acetylthiocholine was used as a substrate and hydrolysis of 
acetylthiocholine was determined by monitoring the formation of the 
yellow 5-thio-2-nitrobenzoate anion as a result of the reaction with 
DTNB with thiocholine catalyzed by enzymes at a wavelength of 412 nm. 
Briefly, 25 μl of 15 mm ATCI, (43 mg/10 ml in Millipore water), 125 μl 
of 3 mm DTNB, (11.9 mg/10 ml buffer B), 50 μl of buffer A, and 20 μl of 
compound at a concentration of 100 μg/ml were added to 96 well plates 
and the absorbance was measured at 412 nm every 13 s for five times. 
After adding 25 μl of 0.22 U/ml enzymes, (0.34 mg AchE dissolved in 
100 ml buffer A), the absorbance was read again every 13 s for five 
times. The absorbance was measured using a Multi-Mode Microplate 
Reader. Percentage of inhibition was calculated by comparing the rates 
of the sample with the blank; control samples contained all components 
except the tested extract. Physostigmine was used as positive control. 
Then, the mean of three measurements for each concentration was 
determined (n=3). Half maximal inhibitory concentration (IC50 value) 
was calculated and listed in the (Table 2).
Statistical analysis
Statistical analysis was carried out using one-way ANOVA. The data are 
represented as in mean±standard deviation.
RESULTS AND DISCUSSION
Degeneration of cholinergic neurons and decrease in ACh levels 
in neocortex, hippocampus, and basal forebrain play a major role 
in the pathophysiology of AD. The pathological hallmark of AD is 
widespread neurotic plaques which are accumulations of amyloid 
beta (Aβ) protein [25]. Production and accumulation of Aβ appear to 
be central to the pathogenesis of AD [26]. Aβ is a short polypeptide of 
about 42 amino acids produced by the abnormal proteolytic cleavage 
of amyloid precursor protein, which involves enzymes-like gamma-
secretase [27]. Production and deposition of Aβ are the central event 
triggering oxidation, lipid peroxidation, and excessive excitotoxicity 
of glutamatergic neurons, inflammation, apoptotic cell death, and 
formation of neurofibrillary tangles [26]. Neurofibrillary tangles are 
paired helical filaments composed of tau protein, which in normal 
cells are essential for axonal growth and development [28]. However, 
when hyperphosphorylated, the tau protein forms tangles that are 
systematically deposited within neurons located in the hippocampus 
and medial temporal lobe, the parietotemporal region, and the frontal 
association cortices leading to cell death [29-31]. The cell death in 
the basal forebrain (nucleus basalis of meynert) leads to deficit in 
neurotransmitter systems of ACh, serotonin, and norepinephrine. 
Studies report that deficit in cholinergic system is responsible for 
cognitive decline and memory loss in patients with AD [32]. The 
disturbances in neurotransmitter systems also lead to a variety 
of behavioral abnormalities, including depression, psychosis, and 
agitation [33] (Fig. 1).
From Table 2 results, all compounds 3a-j were tested against AChE and 
related IC50±SD were calculated. Compound 3a without substitute on 
Table 2: Acetyl cholinesterase inhibitory activity of the 
compounds 3a-j with IC50 values
S. No. Name of 
compounds












Data presented as mean±SD (n=3). ND: Not determined, SD: Standard deviation, 
IC50: Half maximal inhibitory concentration
Fig. 1: Acetylcholinesterase inhibitory activity of the compounds 
3a-j with half maximal inhibitory concentration values
Table 1: Molecular details of target compounds 3a-j [21]
Entry code R1 R2 R3 Molecular formula
3a H H H C23H19NO
3b Cl H H C23H18ClNO
3c F H H C23H18FNO
3d H Cl H C23H18ClNO
3e H Cl Cl C23H17Cl2NO
3f Cl H Cl C23H17Cl2NO
3g F H Cl C23H17ClNO
3h H Cl F C23H17ClFNO
3i Cl H F C23H17ClFNO
3j F H F C23H17F2NO
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phenyl ring was screened and found to be active. To explore, the effect 
of electron withdrawing halogen substituents along with the propan-
1-one active site, the compound 3j having para fluorine substitution 
on both phenyl ring A and B are the most potent one in the series this 
might be because of bioisosteric replacement of hydrogen by fluorine.
Both para substituted fluorine (3j) was essential for effective 
anticholinesterase activity, but on the other hand only para and meta 
substitution of chlorine on ring A (compound 3b, 3d, 3f, and 3h) it does 
not lead to inhibitory effect even though, the compound 3h having 
para fluorine on ring B compared to other position for this moiety. 
The change in the size by the incorporation of fluorine might alter the 
probability of binding to the enzyme hence lower in activity. Among 
the compounds, 3c, 3g, and 3j with fluorine moiety on ring A exhibited 
anticholinesterase activity. Whereas, compound 3j with fluorine at para 
substitution on the phenyl rings (A and B) exhibited inhibition potency 
when compared with other positions. The activity exhibited by the 
compounds might be due to inhibition of hydrolysis of ACh by AChE by 
binding effectively.
CONCLUSION
A series of 3-(1H-indol-3-yl)-1, 3-diphenylpropan-1-one derivatives 
3a-j were screened for AchE inhibition. Among ten derivatives tested, 
compound 3a, 3c, and 3j with varying substituents on phenyl ring A and 
B exhibited the highest potency in this series (IC50 values of 13.64 16.48 
and 14.3 µg/ml) when compared with physostigmine. The results of the 
enzyme inhibition test (Ellman test) showed that electron withdrawing 
groups such as fluorine can render the best enzyme inhibitory effect on 
para position of the phenyl rings. Synthesized compounds 3a-j could be 
proposed as potential anticholinesterase hits, with further alterations, 
and modifications the molecules might become effective leads in the 
treatment of AD.
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